ByTrending Posts
Will Bayer’s Backing of RedHill’s Opaganib Open New…
Key Takeaways Bayer-Supported Trial Expands Opaganib’s Potential RedHill Biopharma’s collaboration with Bayer has taken center stage with the…
Could Merck’s Oral PCSK9 Inhibitor Enlicitide Transform Cholesterol…
Key Takeaways Breakthrough in Cardiovascular Innovation Merck announced positive topline Phase 3 results for enlicitide decanoate, its investigational…
Could Johnson & Johnson’s 99.7% Acute Success in…
Key Highlights Breakthrough Clinical Data from ESC 2025Johnson & Johnson MedTech unveiled results from the VARIPURE substudy of…
Will Veeva and Amgen’s $50 Billion Industry Push…
Key Highlights: Collaboration to Accelerate Clinical DevelopmentVeeva Systems announced a landmark collaboration with Amgen to transform clinical trial…
Can Johnson & Johnson’s $5B+ Immunology Bet Survive…
Key Highlights: A Trial Disappointment, Not the EndgameJohnson & Johnson announced the discontinuation of nipocalimab development in rheumatoid…
Could Roche and Alnylam’s Phase III Trial of…
Key Highlights Phase II Data Paves the WayThe KARDIA clinical program—spanning three Phase II trials—has provided the foundation…
Can AstraZeneca’s $50B US Investment and Eli Lilly’s…
Key Highlights Virginia Bets Big on Biopharma GrowthVirginia lawmakers have approved significant development packages to draw two of…
Can Cambridge and A*STAR’s New AI Digital Twin…
Key Takeaways AI-Driven Digital Twin for PharmaThe newly launched platform integrates AI with real-time plant data to create…
Can Roche’s $700M Genentech Facility Drive Its $50B…
Key Highlights Strategic Expansion into US ManufacturingGenentech, Roche’s US subsidiary, has broken ground on a new $700M state-of-the-art…
Trending Posts
Latest Stories
Will Johnson & Johnson’s FDA Approval of INLEXZO™ Redefine Bladder Cancer Care After 40 Years of Limited Progress?
Key Highlights: A Breakthrough in Bladder Cancer TreatmentThe U.S. FDA has approved INLEXZO™ (gemcitabine intravesical…
Could Johnson & Johnson’s MARIPOSA Trial with RYBREVANT® + LAZCLUZE® Transform First-Line EGFR-Mutated NSCLC Treatment?
Key Highlights: Clinical Breakthrough in EGFR-Mutated NSCLCJohnson & Johnson’s Innovative Medicine segment has announced positive…
Can Novo Nordisk’s New Semaglutide and Obesity Pipeline Data at EASD 2025 Redefine ‘Food Noise’ Control, Body Composition, and Cardiovascular Outcomes?
Key Highlights: Scientific Momentum at EASD 2025Novo Nordisk will present 35 abstracts across its diabetes…
Could Pfizer and BioNTech’s LP.8.1-Adapted COMIRNATY® Redefine COVID-19 Protection for High-Risk Adults in 2025-2026?
Key Insights: Robust Phase 3 Findings for High-Risk PopulationsThe topline results from the Phase 3…
Gallery
